Max Power

Everything pointing to this being not just a Fabry deal for $SGMO but much l, much more. Wouldn’t be surprised if both HemoA and Fabry go to the same partner. Maybe even open deal for future GTs using the same AAV+Promoter. Beaucoup bucks coming our way.

@meangenebio $SGMO gotta always Sangamo!

$SGMO Fitting that SGMO is down 25% on a day when XBI is up 7.5%

@RNAiAnalyst He created a complete disaster for the entire CGT community....

$sgmo Sandy made it sound like the first wave of Fabry suitors all walked away because of Vinay.

Let’s go!!!

@JustSalPal @BiotechAnalysst Looks like he’s quoting what the analyst said to me.

@BiotechAnalysst lmao this guy stays doing nothing but shitting on other companies in order to hype SGMO.

$QURE William Blair says $SGMO initiated rolling BLA for gene therapy for Fabry ST-920 with expectations it will complete the submission Q2 $QURE has not yet shared eGFR data which is the surrogate endpoint being used by FDA *** path forward for $QURE AMT-130 is #uncertain***

@BiotechAnalysst Those desktop PCs have all been updated to the latest version of Windows. $SGMO

$SGMO all jobs gone

@Soeren_Berlin Thanks @Soeren_Berlin

@BiotechAnalysst @14min mark

just watch it this 10 seconds , its starts right there ...

@Steve72354669 That’s been my rationale

@MaxPowerNGS It is there own fault what is the point of selling at .36 cents a that point you may as well ride it down to zero if it went belly up.

Starting to feel bad about the long-term holders of $SGMO that recently cut bait and sold. This has the hallmarks of the start of a big run.

@Soeren_Berlin $SGMO needs more temporary desktop support specialists to figure out how to send emails out.

$SGMO planned to put out a PR today, but new position still unfilled and Louise called in sick, intern still fighting Gemini over tone — so it might slip to AH or next days… or weeks… In the meantime, Sandy shared the good news with his neighbours. Decentralised communication strategy, hoping for organic distribution. #TakeItWithHumor #joke

@JungleJorge2 Timing can’t be coincidental

Alright $SGMO is up almost 40% on no news. CFO's last official working business day is, oh right, tomorrow. Chances we get a positive announcement tomorrow?

@appalachiangabe $SGMO

$SGMO, of all things, is saving my portfolio from utter disaster.

@ElKapitan57 @BiotechAnalysst @yusufhameed Would imagine $SGMO structures spinout into some advantageous cash sale to address near term liquidity issues while retaining some upside. Essentially a partnership, but scale of spinout deal (multiple techs and INDs) requires time.

@MaxPowerNGS @BiotechAnalysst @yusufhameed So, what might the stock value do?

VP position is still actively listed on LinkedIn as of now (posted by $SGMO directly). It's tied to their ongoing push toward potential approval/commercialization of assets like ST-920 (their Fabry disease gene therapy candidate) and related partnership or regulatory milestones by @SangamoTx). It's tied to their ongoing push toward potential approval/commercialization of assets like ST-920 (their Fabry disease gene therapy candidate) and related partnership or regulatory milestones.

@kaysaaa81 @BiotechAnalysst @Franca_ole @ZinselmeyerB @BioStocks @BiotechCH If BP wants the AAV and promoter for $SGMO gene therapy that would make sense for everyone. $SGMO GT can be repurposed for several diseases and that tech platform is not to $SGMO anymore. If BP wants Fabry+HemoA+others that’s great - they just gotta pay for it.

$SGMO @BiotechAnalysst @Franca_ole @ZinselmeyerB @BioStocks @BiotechCH Been thinking about this impasse of no deal announcement. The standoff at $SGMO might simply be this: BP wants Fabry and the platform behind it. By picking up both BP gains maximum long-term value. SGMO wants cash from Fabry but to keep the platform for future gene therapies. With limited leverage, that tension explains the delay it’s about control & price, not science. Just my two cents or should I say 40 cents!

@BiotechAnalysst @SangamoTx $sgmo

another example of $SGMO cancelling: doing a reports about Gene Editing #Intergrase and not mentioning #MINT or @sangamotx ... but showing how CRISPR can NOT do it and others need multiple tools to deliver and fail: at least calling out $NTLA old tech and Qs they are facing now

Ptosis humor is the best humor. #ophthalmology

@809trader When the deal is announced at #jpm26 the $SGMO shorts will get crushed.

$SGMO short interest up again 🤔 this makes zero sense. Who the fuck is shorting a 0.45 stock?

@BiotechAnalysst This adverse event resolves quickly though…can $PFE keep charging them for their weekly therapy afterwards?

JUST DEATH $PFE